Evolus (NASDAQ:EOLS) Price Target Increased to $20.00 by Analysts at Barclays

Evolus (NASDAQ:EOLS) had its price objective raised by Barclays from $16.00 to $20.00 in a research note released on Friday morning, Benzinga reports. Barclays currently has an overweight rating on the stock.

A number of other research firms have also recently weighed in on EOLS. Cantor Fitzgerald reaffirmed an overweight rating on shares of Evolus in a report on Monday, September 9th. HC Wainwright reaffirmed a buy rating and set a $27.00 target price on shares of Evolus in a research note on Thursday, August 1st. Finally, Needham & Company LLC reissued a buy rating and issued a $22.00 price target on shares of Evolus in a research note on Friday.

Evolus Price Performance

Shares of EOLS opened at $16.77 on Friday. Evolus has a 12 month low of $7.44 and a 12 month high of $17.70. The company has a debt-to-equity ratio of 6.26, a current ratio of 2.92 and a quick ratio of 2.67. The stock has a fifty day moving average price of $13.76 and a 200 day moving average price of $13.04. The company has a market cap of $1.06 billion, a P/E ratio of -16.88 and a beta of 1.31.

Evolus (NASDAQ:EOLS) last released its quarterly earnings data on Wednesday, July 31st. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). The company had revenue of $66.91 million for the quarter, compared to analyst estimates of $65.06 million. On average, research analysts forecast that Evolus will post -0.64 earnings per share for the current year.

Insider Transactions at Evolus

In related news, CFO Sandra Beaver sold 3,276 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $14.98, for a total transaction of $49,074.48. Following the transaction, the chief financial officer now owns 148,502 shares in the company, valued at $2,224,559.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Evolus news, CFO Sandra Beaver sold 3,276 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $14.98, for a total value of $49,074.48. Following the completion of the sale, the chief financial officer now directly owns 148,502 shares in the company, valued at $2,224,559.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of Evolus stock in a transaction on Friday, August 30th. The shares were sold at an average price of $15.85, for a total value of $89,251.35. Following the transaction, the chief marketing officer now owns 82,375 shares in the company, valued at $1,305,643.75. The disclosure for this sale can be found here. Company insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of EOLS. Quarry LP acquired a new stake in Evolus in the 2nd quarter valued at about $54,000. Algert Global LLC bought a new stake in shares of Evolus in the 2nd quarter worth approximately $210,000. The Manufacturers Life Insurance Company raised its holdings in shares of Evolus by 36.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,825 shares of the company’s stock worth $237,000 after purchasing an additional 5,808 shares in the last quarter. AQR Capital Management LLC lifted its stake in Evolus by 33.3% during the second quarter. AQR Capital Management LLC now owns 72,007 shares of the company’s stock valued at $781,000 after purchasing an additional 17,971 shares during the last quarter. Finally, Armistice Capital LLC bought a new stake in Evolus during the second quarter worth approximately $3,906,000. 90.69% of the stock is owned by institutional investors and hedge funds.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.